title: The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
authors.forename: David
authors.initials: D
authors.lastname: Wong
authors.forename: Antonia M
authors.initials: AM
authors.lastname: Joussen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab; D002423:Cause of Death; D006470:Hemorrhage / Q000209:etiology / Q000401:mortality*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality*; D010778:Photochemotherapy / Q000009:adverse effects; D000069579:Ranibizumab; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000401:mortality*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab